AVXL

Over the past six months (March 2026 - September 2026), Anavex Life Sciences Corp.'s stock (AVXL) declined by 39.16%, and by 72.20% over the past year. In March 2026, Anavex withdrew its marketing authorization application for blarcamesine in the European Union due to negative regulatory feedback. In May 2026, the Board of Directors terminated CEO Christopher Missling for conduct inconsistent with company policy, appointing Terrie Kellmeyer as Interim CEO. By September 2026, PVG Asset Management, a significant shareholder, announced plans for a proxy battle to replace the Board and hire an experienced CEO, with proxy advisory firm Glass Lewis recommending support for two new PVG nominees due to governance concerns, leadership issues, and compliance problems.